PureTech, a science and technology R&D company focused on identifying, inventing and commercializing disruptive products and technologies in the healthcare sector, has announced the appointment of Christopher Viehbacher, former CEO and Member of the Board of Directors of Sanofi, to its Board of Directors.
Takeda Pharmaceutical Co., Japan's largest drug company, has expanded its Singapore operations...
Turing Pharmaceuticals AG announced its official launch today, along with news of three...
Alkermes has appointed Mark Namchuk, Ph.D., as Senior Vice President of Research, Pharmaceutical...
Astellas has announced organizational and personnel changes in the Americas, highlighting the company's focus on international markets, while also building new Corporate Affairs and Corporate Development functions.
Sanofi said Thursday Brandicourt, 59, will start on April 2. He has been Bayer HealthCare's chairman and CEO since November 2013, and was also an executive for Pfizer Inc.
Horizon Pharma, a specialty biopharmaceutical company, today announced it has opened a Chicago office. The office, which is located at 150 South Wacker Drive, will primarily house commercial, corporate analytics and business development staff.
The company announced the overhaul of its HealthCare, CropScience and other operations in a letter sent to employees Wednesday, though it indicated specific decisions on what the company will look like next January haven't yet been made.
Sanofi SA acknowledged the job cuts in its Genzyme division Wednesday. The layoffs will largely effect facilities in Cambridge, with about 70 at the rare disease-focused Sanofi Genzyme Research and Development Center and 30 at a smaller cancer research center.
Catalent has appointed Thomas Castellano as Vice President Finance, Investor Relations, and Treasurer effective immediately. Mr. Castellano joined Catalent in 2008 when the Company formed its Financial Planning and Analysis (FP&A) group and was actively involved in building out its financial operations.
Margaret Hamburg told employees of the FDA in an email that the agency's chief scientist, Stephen Ostroff, will serve as acting commissioner. She is among the longest-serving commissioners to head the agency and helped oversee the creation of a new food safety system, reforms in how drugs are reviewed and new tobacco regulations.
The Advanced Medical Technology Association said the tax -- which was enacted as part of the Affordable Care Act to generate revenue for the law -- resulted in 4,500 job reductions in 2014.
Epizyme has announced that Robert A. Copeland, Ph.D., has been named President of Research. Dr. Copeland, who was previously Executive Vice President of Research and Chief Scientific Officer at Epizyme, will continue to serve as Chief Scientific Officer.
Alexion Pharmaceuticals announced that its Board of Directors has appointed David L. Hallal as the Company’s Chief Executive Officer (CEO), effective April 1, 2015. Mr. Hallal currently serves as Alexion’s Chief Operating Officer (COO) and is a Director of the Board.
U.S. Food and Drug Administration Commissioner Margaret A. Hamburg, M.D., has appointed Robert Califf, M.D., a recognized global leader in cardiology, clinical research, and medical economics, as FDA Deputy Commissioner for Medical Products and Tobacco.
The Pharma & Biopharma Outsourcing Association (PBOA) today announced that Nelson Patterson, Vice President, Sales and Marketing at Baxter BioPharma Solutions, has been elected to its Board of Trustees, effective immediately. Mr. Patterson was elected after Baxter BioPharma Solutions joined the PBOA as a Sustaining Member.
Bristol-Myers Squibb has named its chief operation officer, Giovanni Caforio, as its new CEO. He will take over after the company's annual shareholders' meeting on May 5, replacing current CEO, Lamberto Andreotti.
U.S. employers advertised the most job openings in nearly 14 years in November, the Labor Department said Tuesday. That suggests businesses are determined to keep adding staff because they are confident strong economic growth will create more demand for their goods and services.
AMRI has announced that Michael M. Nolan, senior vice president and chief financial officer, will be departing AMRI. Nolan will remain with AMRI through February 2015 to support an orderly transition.The company also announced that Felicia Ladin will join the company in the same role, effective February 4, 2015.
On January 1, 2015 the Life Science Industry lost one of its greatest and most distinguished leaders,Tom Tappen of Fluid Air, a division of Spraying Systems Co. Tom's dedication, passion and expertise in the pharmaceutical industry can never be replaced.
Endo International has announced changes to its executive leadership and senior management team. The changes are designed to support Endo's continued evolution into a leading global specialty healthcare company and accelerate growth both organically and through corporate development activities.
KaloBios Pharmaceuticals announced that David W. Pritchard, president and chief executive officer, has decided to retire, effective immediately, and has also resigned his position as a member of the company's Board of Directors.
Salix Pharmaceuticals has announced that Carolyn Logan has informed the Board of her decision to retire as President and Chief Executive Officer, and as a director, of the Company, effective January 30, 2015.
Sprout Pharmaceuticals today announced that Cindy Whitehead has been named CEO, effective immediately. Cindy co-founded Sprout Pharmaceuticals and previously served as president and chief operating officer.
Endo International announced today that Caroline B. Manogue, Executive Vice President, Chief Legal Officer has advised the company that she intends to retire from the company on July 1, 2015.
Cellceutix Corporation, a clinical stage biopharmaceutical company developing therapies with oncology, dermatology and antimicrobial applications, has announced that Daniel Jorgenson MD, MPH, MBA will join the Cellceutix team as Chief Medical Officer as of January 1, 2015.
United Therapeutics Corporation has announced two senior executive promotions as well as changes to Martine Rothblatt, Ph.D's compensation program.
Actavis has announced the planned senior management team that will lead the global pharmaceutical company following the successful close of the acquisition of Allergan anticipated in the second quarter of 2015.
Gilead Sciences has announced that Philippe C. Bishop, MD, will join the company as Senior Vice President, Hematology and Oncology Therapeutics. In this position, Dr. Bishop will report to John McHutchison, MD, Executive Vice President, Clinical Research.
- Page 1